Others

Haihe Biopharma's Liporaxel Wins NMPA Approval for HER2‑Negative Breast Cancer – World's First Oral Paclitaxel Expands into Second Indication in China
3SBioHaihe Biopharma

Haihe Biopharma’s Liporaxel Wins NMPA Approval for HER2‑Negative Breast Cancer – World’s First Oral Paclitaxel Expands into Second Indication in China

Shanghai Haihe Biopharma Co., Ltd, a partner of 3SBio Inc. (HKG: 1530), announced that its paclitaxel oral solution (registered trademark: Liporaxel; development code: RMX3001/DHP107), developed in collaboration with South Korea‑based…

Humanwell Healthcare Subsidiary Wins FDA ANDA Approval for Diltiazem Hydrochloride Tablets – Expanding U.S. Generic Cardiovascular Portfolio

Humanwell Healthcare Subsidiary Wins FDA ANDA Approval for Diltiazem Hydrochloride Tablets – Expanding U.S. Generic Cardiovascular Portfolio

AbbVie Secures Dual FDA Breakthrough Therapy Designations for Temab‑A in Colorectal and Lung Cancers – Next‑Gen c‑Met ADC Advances

AbbVie Secures Dual FDA Breakthrough Therapy Designations for Temab‑A in Colorectal and Lung Cancers – Next‑Gen c‑Met ADC Advances

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Eisai Announces Commercial Release of Urece (Dotinurad) from Suzhou Facility in China
TYO: 4523

Eisai Announces Commercial Release of Urece (Dotinurad) from Suzhou Facility in China

Chia Tai Tianqing's Anlotinib Granted NMPA Approval for Soft Tissue Sarcoma
Chia Tai Tianqing Pharmaceutical

Chia Tai Tianqing’s Anlotinib Granted NMPA Approval for Soft Tissue Sarcoma

Guangdong Announces First Batch of Approved Innovative Drugs and Medical Devices

Guangdong Announces First Batch of Approved Innovative Drugs and Medical Devices

Viatris Announces Positive Results in VEGA-3 Trial for MR-141 Presbyopia Treatment
NASDAQ: VTRSViatris

Viatris Announces Positive Results in VEGA-3 Trial for MR-141 Presbyopia Treatment

Show More